<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">

<channel>
	<title>THE "NEW"  PROSTATE CANCER INFOLINK</title>
	
	<link>http://prostatecancerinfolink.net</link>
	<description />
	<lastBuildDate>Sat, 11 Jul 2009 10:18:43 +0000</lastBuildDate>
	<generator>http://wordpress.com/</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<image>
		<url>http://www.gravatar.com/blavatar/60ddbc6943ab373dc303c83d1a064c54?s=96&amp;d=http://s.wordpress.com/i/buttonw-com.png</url>
		<title>THE "NEW"  PROSTATE CANCER INFOLINK</title>
		<link>http://prostatecancerinfolink.net</link>
	</image>
			<atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" href="http://feeds.feedburner.com/TheProstateCancerInfolink" type="application/rss+xml" /><feedburner:emailServiceId>TheProstateCancerInfolink</feedburner:emailServiceId><feedburner:feedburnerHostname>http://feedburner.google.com</feedburner:feedburnerHostname><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com" /><item>
		<title>Managing the side effects of bicalutamide monotherapy</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/QtnJnV045Fc/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/11/managing-the-side-effects-of-bicalutamide-monotherapy/#comments</comments>
		<pubDate>Sat, 11 Jul 2009 10:18:43 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[bicalutamide]]></category>
		<category><![CDATA[monotherapy]]></category>
		<category><![CDATA[pprophylaxis]]></category>
		<category><![CDATA[tamoxifen]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6377</guid>
		<description><![CDATA[In Europe, bicalutamide monotherapy with a dose of 150 mg/d is a widely used option for prostate cancer patients who wish to avoid the consequences of standard androgen deprivation using an LHRH agonist such as leuprolide acetate. However, bicalutamide induces gynecomastia (enlargement of the breasts) and mastalgia/mastodynia (pain in the breasts) in most patients.
Once-daily tamoxifen [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6377&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/11/managing-the-side-effects-of-bicalutamide-monotherapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/11/managing-the-side-effects-of-bicalutamide-monotherapy/</feedburner:origLink></item>
		<item>
		<title>Living “without treatment”: how men respond to active surveillance</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/VmbWyBOy6ok/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/10/living-without-treatment-how-men-respond-to-active-surveillance/#comments</comments>
		<pubDate>Fri, 10 Jul 2009 14:14:54 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[active surveillance]]></category>
		<category><![CDATA[quality of life]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6370</guid>
		<description><![CDATA[Better understanding of how different men respond to the uncertainty and quality of life issues associated with active surveillance as a method to manage low- and intermediate-risk prostate cancer has the potential to enhance the delivery of  care for such patients.
Hegarty et al. set out to enhance our understanding of the experience of active [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6370&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/10/living-without-treatment-how-men-respond-to-active-surveillance/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/10/living-without-treatment-how-men-respond-to-active-surveillance/</feedburner:origLink></item>
		<item>
		<title>Screening and cancer: the controversies are spreading</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/7u3uZCHaU80/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/10/screening-and-cancer-the-controversies-are-spreading/#comments</comments>
		<pubDate>Fri, 10 Jul 2009 13:17:28 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[screening]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6368</guid>
		<description><![CDATA[As we have suggested before in these reports, the question of whether mass, population-based screening for certain cancers (including prostate cancer) is really the best strategy for prevention of risk from the disease itself is a complex one.
A new article, published this week in BMJ, addresses this issue with specific focus on the use of [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6368&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/10/screening-and-cancer-the-controversies-are-spreading/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/10/screening-and-cancer-the-controversies-are-spreading/</feedburner:origLink></item>
		<item>
		<title>Prostate cancer news reports: Thursday, July 9, 2009</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/J2fPaKkOjxQ/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/09/prostate-cancer-news-reports-thursday-july-9-2009/#comments</comments>
		<pubDate>Thu, 09 Jul 2009 14:13:12 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Prevention]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[finasteride]]></category>
		<category><![CDATA[LHRH agonist]]></category>
		<category><![CDATA[nitric oxide]]></category>
		<category><![CDATA[risk]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6362</guid>
		<description><![CDATA[Today&#8217;s news reports address such items as:

Finasteride in the prevention of prostate cancer
Nitric oxide treatment in men with a rising PSA after first-line therapy
Decreased use of LHRH agonist therapy since 2003

A new report by Elliott et al. has confirmed the earlier suggestions by the authors of the Prostate Cancer Prevention Trial results that there is [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6362&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/09/prostate-cancer-news-reports-thursday-july-9-2009/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/09/prostate-cancer-news-reports-thursday-july-9-2009/</feedburner:origLink></item>
		<item>
		<title>Prostate cancer news reports: Wednesday, July 8, 2009</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/OsmOs2Q3mSk/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/08/prostate-cancer-news-reports-wednesday-july-8-2009/#comments</comments>
		<pubDate>Thu, 09 Jul 2009 01:34:25 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[Actonel]]></category>
		<category><![CDATA[brachytherapy]]></category>
		<category><![CDATA[cryotherapy]]></category>
		<category><![CDATA[estradiol]]></category>
		<category><![CDATA[Gleason score]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[permanent]]></category>
		<category><![CDATA[quality of life]]></category>
		<category><![CDATA[risedronate]]></category>
		<category><![CDATA[seed]]></category>
		<category><![CDATA[survey]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6353</guid>
		<description><![CDATA[Today&#8217;s prostate cancer news reports cover items on:

Assessment of quality of life after radical prostatectomy
Permanent seed brachytherapy in treatment of localized disease
Cryotherapy in treatment of patients with Gleason 8-10 localized disease
Actonel and/or estradiol in prevention of SREs

Hedgepeth et al. have compared the value of three different prostate cancer outcome survey tools in the assessment of [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6353&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/08/prostate-cancer-news-reports-wednesday-july-8-2009/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/08/prostate-cancer-news-reports-wednesday-july-8-2009/</feedburner:origLink></item>
		<item>
		<title>And now for some light entertainment</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/k16dQHDtK2A/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/08/and-now-for-some-light-entertainment/#comments</comments>
		<pubDate>Wed, 08 Jul 2009 17:08:01 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[PSA test]]></category>
		<category><![CDATA[risk]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6344</guid>
		<description><![CDATA[A Swiss prostate cancer research trust (Stiftung Prostrata) paired with ad agency Jung von Matt/Limatt to come up an eye-catching series of print advertisements encouraging men to get a PSA test.



What looks like a series of photos of men in their underwear is cleverly and humorously turned into a demonstration of the power of early [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6344&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/08/and-now-for-some-light-entertainment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>

		<media:content url="http://talkaboutprostatecancer.files.wordpress.com/2009/07/prostate-slip.jpg" medium="image">
			<media:title type="html">prostate-slip</media:title>
		</media:content>

		<media:content url="http://talkaboutprostatecancer.files.wordpress.com/2009/07/prostate_boxer.jpg" medium="image">
			<media:title type="html">prostate_boxer</media:title>
		</media:content>

		<media:content url="http://talkaboutprostatecancer.files.wordpress.com/2009/07/prostate_thong.jpg" medium="image">
			<media:title type="html">prostate_thong</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/08/and-now-for-some-light-entertainment/</feedburner:origLink></item>
		<item>
		<title>Prostate cancer: what treatment costs in the first year</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/FT-IG9sljXc/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/08/prostate-cancer-what-treatment-costs-in-the-first-year/#comments</comments>
		<pubDate>Wed, 08 Jul 2009 16:47:34 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[cost]]></category>
		<category><![CDATA[first year]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6342</guid>
		<description><![CDATA[An analysis by Roehrborn et al. has come up with a mean, per-patient cost of just over $13,000 for managing the care of a newly diagnosed prostate cancer patient for the first year after his diagnosis in the USA, inclusive of actual treatment costs.
We are obviously in no position to make a judgment about the [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6342&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/08/prostate-cancer-what-treatment-costs-in-the-first-year/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/08/prostate-cancer-what-treatment-costs-in-the-first-year/</feedburner:origLink></item>
		<item>
		<title>Generic bicalutamide now available in the USA</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/Ey4r8Mj7-eU/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/08/generic-bicalutamide-now-available-in-the-usa/#comments</comments>
		<pubDate>Wed, 08 Jul 2009 15:31:14 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[bicalutamide]]></category>
		<category><![CDATA[Casodex]]></category>
		<category><![CDATA[generic]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6339</guid>
		<description><![CDATA[According to a report from the Associated Press, generic bicalutamide (the generic form of Casodex) is now available in the USA after approval by the US Food and Drug Administration. This offers a significant potential cost saving for many prostate cancer patients that they may want to take advantage of.
Posted in Living with Prostate Cancer, [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6339&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/08/generic-bicalutamide-now-available-in-the-usa/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/08/generic-bicalutamide-now-available-in-the-usa/</feedburner:origLink></item>
		<item>
		<title>Prostate cancer as a poster child for health care reform</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/bFcw7dOXDaM/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/08/prostate-cancer-as-a-poster-child-for-health-care-reform/#comments</comments>
		<pubDate>Wed, 08 Jul 2009 12:17:11 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[reform]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6335</guid>
		<description><![CDATA[Some (maybe many) readers of this column are not going to like an article on the front page of the New York Times today.
The author of this piece, David Leonhardt, looks at prostate cancer management as an economist, not as a patient, and focuses on something we all understand but tend not to want to [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6335&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/08/prostate-cancer-as-a-poster-child-for-health-care-reform/feed/</wfw:commentRss>
		<slash:comments>6</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/08/prostate-cancer-as-a-poster-child-for-health-care-reform/</feedburner:origLink></item>
		<item>
		<title>Is denosumab “better” than Zometa at preventing skeletal events?</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/uC3soM44BTg/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/07/is-denosumab-better-than-zometa-at-preventing-skeletal-events/#comments</comments>
		<pubDate>Wed, 08 Jul 2009 02:44:43 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[denosumab]]></category>
		<category><![CDATA[skeletal-related events]]></category>
		<category><![CDATA[SREs]]></category>
		<category><![CDATA[zoledronate]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6333</guid>
		<description><![CDATA[Amgen, the developer of denosumab (also known as RANK-L) has released data today from a head-to-head trial of their drug vs. zoledronate (Zometa) in the management of patients with advanced breast cancer and bone metastases.
Although these are not data from prostate cancer patients, historic experience has shown that drugs like zoledronate and denosumab tend to [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6333&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/07/is-denosumab-better-than-zometa-at-preventing-skeletal-events/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/07/is-denosumab-better-than-zometa-at-preventing-skeletal-events/</feedburner:origLink></item>
		<item>
		<title>GTX-758 in treatment of prostate cancer</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/F_IyOe15yK8/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/07/gtx-758-in-treatment-of-prostate-cancer/#comments</comments>
		<pubDate>Tue, 07 Jul 2009 23:24:57 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[GTx]]></category>
		<category><![CDATA[GTx-758]]></category>
		<category><![CDATA[inhibitor]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[luteinizing hormone]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6329</guid>
		<description><![CDATA[GTx has announced a second Phase I clinical trial evaluating GTx-758, an oral luteinizing hormone (LH) inhibitor (not an LHRH agonist or an LHRH antagonist), for first-line treatment of advanced prostate cancer.
A prior Phase I clinical trial in 96 subjects was completed in June.
The ongoing Phase I multiple ascending dose clinical trial will evaluate the [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6329&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/07/gtx-758-in-treatment-of-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/07/gtx-758-in-treatment-of-prostate-cancer/</feedburner:origLink></item>
		<item>
		<title>Prostate cancer news reports: Tuesday, July 7, 2009</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/vlj_K5UV2eQ/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/07/prostate-cancer-news-reports-tuesday-july-7-2009/#comments</comments>
		<pubDate>Tue, 07 Jul 2009 11:31:28 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[age]]></category>
		<category><![CDATA[best practices]]></category>
		<category><![CDATA[external beam radiation]]></category>
		<category><![CDATA[nomogram]]></category>
		<category><![CDATA[PSA]]></category>
		<category><![CDATA[salvage]]></category>
		<category><![CDATA[single nucleotide polymorphism]]></category>
		<category><![CDATA[SNP]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6322</guid>
		<description><![CDATA[In today&#8217;s news reports we address new data on:

The possible association between PSA levels and SNPs
Patient age at diagnosis and prostate cancer outcomes
Revalidation of the Stephenson nomogram for outcomes after salvage radiation therapy
Failure to follow best practices for radiation of bony metastases

Loeb et al. have published data suggesting that the presence of certain specific single [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6322&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/07/prostate-cancer-news-reports-tuesday-july-7-2009/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/07/prostate-cancer-news-reports-tuesday-july-7-2009/</feedburner:origLink></item>
		<item>
		<title>New addition to Scientific Advisory Board</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/S1N-00oUl0E/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/06/new-addition-to-scientific-advisory-board/#comments</comments>
		<pubDate>Mon, 06 Jul 2009 17:51:27 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6315</guid>
		<description><![CDATA[We are pleased to announce that Mark Emberton, MD, FRCS has accepted an invitation to join the Scientific Advisory Board of The &#8220;New&#8221; Prostate Cancer InfoLink.
Mr. Emberton is a clinical researcher with particular interest in minimally invasive forms of treatment for localized prostate cancer. (And for those unfamiliar with this terminology, surgeons in the UK, [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6315&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/06/new-addition-to-scientific-advisory-board/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/06/new-addition-to-scientific-advisory-board/</feedburner:origLink></item>
		<item>
		<title>Of black and white and shades of grey</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/0uNiJktG0GA/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/05/of-black-and-white-and-shades-of-grey/#comments</comments>
		<pubDate>Sun, 05 Jul 2009 13:09:40 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[screening]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6310</guid>
		<description><![CDATA[For many years now, the prostate cancer &#8220;screening&#8221; issue has been framed by two opposing and &#8220;extreme&#8221; points of view.
On the one hand, much of the urology community and many in the survivor community have argued that regular testing of all men over some specific age is essential if we are to find and treat [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6310&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/05/of-black-and-white-and-shades-of-grey/feed/</wfw:commentRss>
		<slash:comments>12</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/05/of-black-and-white-and-shades-of-grey/</feedburner:origLink></item>
		<item>
		<title>HIFU for localized prostate cancer: a series of 172 UK patients</title>
		<link>http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/g1bpM2N1yCM/</link>
		<comments>http://prostatecancerinfolink.net/2009/07/04/hifu-for-localized-prostate-cancer-a-series-of-172-uk-patients/#comments</comments>
		<pubDate>Sat, 04 Jul 2009 20:01:29 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[HIFU]]></category>
		<category><![CDATA[high-intensity focused ultrasound]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=6296</guid>
		<description><![CDATA[The following commentary reports with greater accuracy and in more detail on the same article, dealing with the same series of 172 HIFU patients, as was previously discussed on this web site on July 2 this year. The original report was based solely on the abstract of the article. The current report has been posted [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&blog=3176292&post=6296&subd=talkaboutprostatecancer&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2009/07/04/hifu-for-localized-prostate-cancer-a-series-of-172-uk-patients/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	<feedburner:origLink>http://prostatecancerinfolink.net/2009/07/04/hifu-for-localized-prostate-cancer-a-series-of-172-uk-patients/</feedburner:origLink></item>
	</channel>
</rss>
